BLOXIVERZ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bloxiverz, and when can generic versions of Bloxiverz launch?
Bloxiverz is a drug marketed by Exela Pharma and is included in one NDA.
The generic ingredient in BLOXIVERZ is neostigmine methylsulfate. There are nine drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the neostigmine methylsulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bloxiverz
A generic version of BLOXIVERZ was approved as neostigmine methylsulfate by FRESENIUS KABI USA on January 8th, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BLOXIVERZ?
- What are the global sales for BLOXIVERZ?
- What is Average Wholesale Price for BLOXIVERZ?
Summary for BLOXIVERZ
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 104 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,171 |
| Drug Prices: | Drug price information for BLOXIVERZ |
| What excipients (inactive ingredients) are in BLOXIVERZ? | BLOXIVERZ excipients list |
| DailyMed Link: | BLOXIVERZ at DailyMed |
Recent Clinical Trials for BLOXIVERZ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Missouri-Columbia | Phase 4 |
| Merck Sharp & Dohme LLC | Phase 4 |
Pharmacology for BLOXIVERZ
| Drug Class | Cholinesterase Inhibitor |
| Mechanism of Action | Cholinesterase Inhibitors |
US Patents and Regulatory Information for BLOXIVERZ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exela Pharma | BLOXIVERZ | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 204078-001 | May 31, 2013 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Exela Pharma | BLOXIVERZ | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 204078-003 | Oct 27, 2023 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Exela Pharma | BLOXIVERZ | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 204078-002 | May 31, 2013 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
